Guy's and St Thomas' NHS Foundation Trust, London, UK.
University Hospital Birmingham, Birmingham, UK.
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):627-633. doi: 10.1016/j.ijrobp.2017.05.052. Epub 2017 Jun 9.
Total skin electron beam radiation therapy (TSEB) is a very effective treatment of mycosis fungoides. Following reports of similar durations of response to lower doses of TSEB, a low-dose schedule of TSEB was introduced in the United Kingdom.
A protocol of 12 Gy in 8 fractions over a period of 2 weeks was agreed on by use of the Stanford University technique. Data were collected prospectively, and the results were analyzed according to the European Organisation for Research and Treatment of Cancer-International Society for Cutaneous Lymphomas endpoints (EORTC-ISCL). Toxicity was scored according to CTCAE v4.0 (Common Terminology Criteria for Adverse Events version 4.0).
One hundred three patients received treatment, with a median follow-up period of 20.6 months (range, 3.3-53 months). Of these patients, 54 had stage IB disease, 33 had stage IIB, 12 had stage III, and 4 had stage IV. The median age was 68 years (range, 26-91 years). The complete response rate was 18%, the partial response rate was 69%, stable disease was present in 8%, and progression on treatment was found in 5%. In the patients who had a complete response, the median time to relapse was 7.3 months. The median response duration was 11.8 months. Median progression-free survival for all patients was 13.2 months. It was significantly longer, at 26.5 months, in patients with stage IB disease compared with 11.3 months in patients with stage IIB (P=.003; hazard ratio, 2.66) and 10.2 months in patients with stage III (P=.002; hazard ratio, 4.62). The treatment was well tolerated with lower toxicity than higher-dose schedules.
The low-dose TSEB schedule of 12 Gy in 8 fractions over a period of 2 weeks is well tolerated and is an effective option for patients with mycosis fungoides.
全身电子束放射治疗(TSEB)是蕈样肉芽肿的一种非常有效的治疗方法。在报道了类似剂量的 TSEB 反应持续时间后,英国引入了 TSEB 的低剂量方案。
采用斯坦福大学技术,同意采用 12Gy 分 8 次,2 周内完成的方案。数据前瞻性收集,根据欧洲癌症研究与治疗组织-国际皮肤淋巴瘤协会(EORTC-ISCL)终点进行分析。毒性根据 CTCAE v4.0(不良事件常用术语标准 4.0 版)进行评分。
103 例患者接受了治疗,中位随访时间为 20.6 个月(范围 3.3-53 个月)。这些患者中,54 例为 IB 期疾病,33 例为 IIB 期,12 例为 III 期,4 例为 IV 期。中位年龄为 68 岁(范围 26-91 岁)。完全缓解率为 18%,部分缓解率为 69%,疾病稳定率为 8%,治疗进展率为 5%。在完全缓解的患者中,中位复发时间为 7.3 个月。中位缓解持续时间为 11.8 个月。所有患者的中位无进展生存期为 13.2 个月。IB 期患者明显更长,为 26.5 个月,而 IIB 期患者为 11.3 个月(P=.003;风险比,2.66),III 期患者为 10.2 个月(P=.002;风险比,4.62)。治疗耐受性良好,毒性低于高剂量方案。
每周 2 周内完成 12Gy 分 8 次的 TSEB 低剂量方案耐受性良好,是蕈样肉芽肿患者的有效选择。